ofloxacin has been researched along with Leprosy in 77 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
Leprosy: A chronic granulomatous infection caused by MYCOBACTERIUM LEPRAE. The granulomatous lesions are manifested in the skin, the mucous membranes, and the peripheral nerves. Two polar or principal types are lepromatous and tuberculoid.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Dapsone (DDS), Rifampicin (RIF) and Ofloxacin (OFL) are drugs recommended by the World Health Organization (WHO) for the treatment of leprosy." | 9.22 | Drug Resistance (Dapsone, Rifampicin, Ofloxacin) and Resistance-Related Gene Mutation Features in Leprosy Patients: A Systematic Review and Meta-Analysis. ( Jin, G; Li, G; Li, X; Li, Y; Shao, Y; Wei, P; Yang, J; Zhang, L, 2022) |
| "Monthly doses of rifampin, ofloxacin, and minocycline (ROM) are expected to be effective treatment for multi-bacillary leprosy." | 9.11 | Parallel assessment of 24 monthly doses of rifampin, ofloxacin, and minocycline versus two years of World Health Organization multi-drug therapy for multi-bacillary leprosy. ( Abalos, RM; Balagon, MV; Cellona, RV; Dela Cruz, EC; Fajardo, TT; Tan, EV; Villahermosa, LG; Walsh, DS; Walsh, GP, 2004) |
| "The results of ofloxacin containing combined drug regimens in the treatment of 60 multibacillary leprosy cases from January 1989 to June 1995 are reported." | 9.08 | Ofloxacin containing combined drug regimens in the treatment of multibacillary leprosy. ( Bampenyu, S; Bundit, C; Kampirapap, K; Kuhacharoen, N; Peerapakorn, S; Poomlek, A; Rungruang, S; Sampoonachot, P; Supanwanit, S; Surasondhi, S; Tiasiri, S; Wiriyawipart, S, 1997) |
| "In 1995, a field trial was implemented in Senegal in order to evaluate the efficacy of a regimen based on the monthly supervised intake of rifampin 600 mg, ofloxacin 400 mg and minocycline 100 mg to treat leprosy." | 9.08 | Field trial on efficacy of supervised monthly dose of 600 mg rifampin, 400 mg ofloxacin and 100 mg minocycline for the treatment of leprosy; first results. ( Cartel, JL; Grosset, JH; Mane, I, 1997) |
| "The results of combined chemotherapy trials with regimens containing ofloxacin and rifampicin for the treatment of 60 multibacillary leprosy cases from January 1989 to September 1995 was reported." | 9.08 | Combined chemotherapy trials with regimens containing ofloxacin and rifampicin for multibacillary leprosy patients. ( Bampenyu, S; Bundit, C; Kampirapap, K; Kuhacharoen, N; Peerapakorn, S; Poomlek, A; Rungruang, S; Sampoonachot, P; Supanwanit, S; Surasondhi, S; Tiasiri, S; Wiriyawipart, S, 1996) |
| "A combination of rifampicin, ofloxacin and minocycline (ROM) is one of the newer recommendations for treatment of leprosy." | 8.87 | Is there a role for rifampicin, ofloxacin and minocycline (ROM) therapy in the treatment of leprosy? Systematic review and meta-analysis. ( Boivin, JF; Jerajani, HR; Setia, MS; Shinde, SS, 2011) |
| "The occurrence of resistance to the current multidrug therapy regimen (specifically dapsone and rifampicin) and to ofloxacin, a secondary antileprosy medication in M." | 8.31 | High frequency of ofloxacin resistance patterns of Mycobacterium leprae from India: An indication to revisit second line anti-leprosy treatment regimen. ( Chhabra, S; Dogra, S; Jain, S; Kaur, M; Minz, RW; Nadeem, M; Narang, T; Pandey, P; Sahu, S; Sharma, A; Sharma, K; Sharma, R; Shilpa, S; Singh, I; Yadav, R, 2023) |
| "This reports a long-term follow-up study on clinical effects of ofloxacin (OFLX)-combined therapy to 14 leprosy patients with various types and stages." | 7.74 | [Long-term follow-up of ofloxacin-combined therapy for leprosy patients]. ( Ishikawa, M; Ozaki, M, 2007) |
| "Molecular detection of rifampin resistance (rpoB analysis) in Mycobacterium leprae was determined for 49 patients who experienced relapse of multibacillary leprosy and for 34 untreated patients." | 7.71 | Molecular detection of rifampin and ofloxacin resistance for patients who experience relapse of multibacillary leprosy. ( Bonnafous, P; Cambau, E; Jarlier, V; Ji, B; Perani, E; Sougakoff, W, 2002) |
| "The bactericidal activities against Mycobacterium leprae of single or multiple doses of various combinations of new antileprosy drugs [minocycline (MINO), clarithromycin (CLARI), ofloxacin (OFLO), and sparfloxacin (SPFX)] and/or rifampin (RMP) were titrated in immunocompetent mice by the proportional bactericidal method." | 7.68 | Bactericidal activities of single or multiple doses of various combinations of new antileprosy drugs and/or rifampin against M. leprae in mice. ( Grosset, JH; Ji, B; Perani, EG; Petinon, C, 1992) |
| "Leprosy affects skin and peripheral nerves, and acute inflammatory type 1 reactions (reversal reaction) can cause neurologic impairment and disabilities." | 5.34 | Mycobacterium leprae DNA associated with type 1 reactions in single lesion paucibacillary leprosy treated with single dose rifampin, ofloxacin, and minocycline. ( Costa, MB; Gillis, TP; Gomes, MK; Krahenbuhl, JL; Martelli, CM; Narahashi, K; Pereira, GA; Rebello, PF; Sousa, AL; Stefani, MM, 2007) |
| "The antimicrobial effects of ofloxacin against Mycobacterium leprae, either alone or in combination with rifampicin and rifabutin, were studied using mouse foot pad assay technique." | 5.29 | In vivo susceptibility of Mycobacterium leprae to ofloxacin either singly or in combination with rifampicin and rifabutin. Anti-leprosy activity of ofloxacin and ansamycins in mice. ( Dhople, AM; Ibanez, MA, 1994) |
| "Dapsone (DDS), Rifampicin (RIF) and Ofloxacin (OFL) are drugs recommended by the World Health Organization (WHO) for the treatment of leprosy." | 5.22 | Drug Resistance (Dapsone, Rifampicin, Ofloxacin) and Resistance-Related Gene Mutation Features in Leprosy Patients: A Systematic Review and Meta-Analysis. ( Jin, G; Li, G; Li, X; Li, Y; Shao, Y; Wei, P; Yang, J; Zhang, L, 2022) |
| "Monthly doses of rifampin, ofloxacin, and minocycline (ROM) are expected to be effective treatment for multi-bacillary leprosy." | 5.11 | Parallel assessment of 24 monthly doses of rifampin, ofloxacin, and minocycline versus two years of World Health Organization multi-drug therapy for multi-bacillary leprosy. ( Abalos, RM; Balagon, MV; Cellona, RV; Dela Cruz, EC; Fajardo, TT; Tan, EV; Villahermosa, LG; Walsh, DS; Walsh, GP, 2004) |
| "The results of combined chemotherapy trials with regimens containing ofloxacin and rifampicin for the treatment of 60 multibacillary leprosy cases from January 1989 to September 1995 was reported." | 5.08 | Combined chemotherapy trials with regimens containing ofloxacin and rifampicin for multibacillary leprosy patients. ( Bampenyu, S; Bundit, C; Kampirapap, K; Kuhacharoen, N; Peerapakorn, S; Poomlek, A; Rungruang, S; Sampoonachot, P; Supanwanit, S; Surasondhi, S; Tiasiri, S; Wiriyawipart, S, 1996) |
| "In 1995, a field trial was implemented in Senegal in order to evaluate the efficacy of a regimen based on the monthly supervised intake of rifampin 600 mg, ofloxacin 400 mg and minocycline 100 mg to treat leprosy." | 5.08 | Field trial on efficacy of supervised monthly dose of 600 mg rifampin, 400 mg ofloxacin and 100 mg minocycline for the treatment of leprosy; first results. ( Cartel, JL; Grosset, JH; Mane, I, 1997) |
| "To develop a fully supervisable, monthly administered regimen for treatment of leprosy, the bactericidal effect of a single-dose combination of ofloxacin (OFLO) and minocycline (MINO), with or without rifampin (RMP), against Mycobacterium leprae was studied in the mouse footpad system and in previously untreated lepromatous leprosy patients." | 5.08 | Bactericidal activity of a single-dose combination of ofloxacin plus minocycline, with or without rifampin, against Mycobacterium leprae in mice and in lepromatous patients. ( Diderot, V; Grosset, J; Ji, B; Lienhardt, C; Perani, E; Sow, S, 1998) |
| "The results of ofloxacin containing combined drug regimens in the treatment of 60 multibacillary leprosy cases from January 1989 to June 1995 are reported." | 5.08 | Ofloxacin containing combined drug regimens in the treatment of multibacillary leprosy. ( Bampenyu, S; Bundit, C; Kampirapap, K; Kuhacharoen, N; Peerapakorn, S; Poomlek, A; Rungruang, S; Sampoonachot, P; Supanwanit, S; Surasondhi, S; Tiasiri, S; Wiriyawipart, S, 1997) |
| "A combination of rifampicin, ofloxacin and minocycline (ROM) is one of the newer recommendations for treatment of leprosy." | 4.87 | Is there a role for rifampicin, ofloxacin and minocycline (ROM) therapy in the treatment of leprosy? Systematic review and meta-analysis. ( Boivin, JF; Jerajani, HR; Setia, MS; Shinde, SS, 2011) |
| "The occurrence of resistance to the current multidrug therapy regimen (specifically dapsone and rifampicin) and to ofloxacin, a secondary antileprosy medication in M." | 4.31 | High frequency of ofloxacin resistance patterns of Mycobacterium leprae from India: An indication to revisit second line anti-leprosy treatment regimen. ( Chhabra, S; Dogra, S; Jain, S; Kaur, M; Minz, RW; Nadeem, M; Narang, T; Pandey, P; Sahu, S; Sharma, A; Sharma, K; Sharma, R; Shilpa, S; Singh, I; Yadav, R, 2023) |
| "Mycobacterium leprae causes leprosy and ofloxacin is used to control this bacterium." | 3.96 | WQ-3810 inhibits DNA gyrase activity in ofloxacin-resistant Mycobacterium leprae. ( Kim, H; Koide, K; Mori, S; Mukai, T; Nakajima, C; Ouchi, Y; Park, JH; Suzuki, Y; Yamaguchi, T, 2020) |
| "From 2009 to 2015, multi-bacillary leprosy cases at sentinel sites of 19 countries were studied for resistance to rifampicin, dapsone and ofloxacin by PCR sequencing of the drug-resistance-determining regions of the genes rpoB, folP1 and gyrA." | 3.88 | Antimicrobial resistance in leprosy: results of the first prospective open survey conducted by a WHO surveillance network for the period 2009-15. ( Cambau, E; Cardona-Castro, N; Cauchoix, B; Cole, ST; Cooreman, EAWD; Gillini, L; Gupta, UD; Hagge, D; Hongseng, W; Indropo, A; Johnson, RC; Kai, M; Lavania, M; Matsuoka, M; Miyamoto, Y; Pannikar, VK; Pemmaraju, VRR; Rosa, PS; Saunderson, P; Srikantam, A; Suffys, P; Vissa, V; Williams, D, 2018) |
| " leprae to dapsone based on the folP1 drug resistance determining region (DRDR), rifampin (rpoB DRDR) and ofloxacin (gyrA DRDR) was evaluated using 211 clinical specimens from leprosy patients, including 156 multibacillary (MB) and 55 paucibacillary (PB) cases." | 3.85 | qPCR-High resolution melt analysis for drug susceptibility testing of Mycobacterium leprae directly from clinical specimens of leprosy patients. ( Araujo, S; Fontes, AB; Goulart, IMB; Goulart, LR; Li, W; Matsuoka, M; Rosa, PS; Scollard, DM; Suffys, P; Truman, RW; Vissa, V; Williams, DL, 2017) |
| "This reports a long-term follow-up study on clinical effects of ofloxacin (OFLX)-combined therapy to 14 leprosy patients with various types and stages." | 3.74 | [Long-term follow-up of ofloxacin-combined therapy for leprosy patients]. ( Ishikawa, M; Ozaki, M, 2007) |
| "Between 1989 and 1993, 136 multibacillary leprosy patients received a 6-week treatment regimen consisting of daily rifampicin 600 mg, ofloxacin 400 mg, clofazimine 100 mg and a weekly dose of 100 mg minocycline." | 3.71 | Relapse rates and a 10-year follow-up of a 6-week quadruple drug regimen for multibacillary leprosy. ( Grillone, S; Pattyn, S, 2002) |
| "Molecular detection of rifampin resistance (rpoB analysis) in Mycobacterium leprae was determined for 49 patients who experienced relapse of multibacillary leprosy and for 34 untreated patients." | 3.71 | Molecular detection of rifampin and ofloxacin resistance for patients who experience relapse of multibacillary leprosy. ( Bonnafous, P; Cambau, E; Jarlier, V; Ji, B; Perani, E; Sougakoff, W, 2002) |
| "The bactericidal activities of 12 regimens with various combinations of new drugs (clarithromycin [CLARI], minocycline [MINO], and ofloxacin [OFLO]) and the standard antileprosy drugs, especially rifampin (RMP), were compared in nude mice with established Mycobacterium leprae infection." | 3.69 | Bactericidal activities of combinations of new drugs against Mycobacterium leprae in nude mice. ( Grosset, JH; Ji, B; Perani, EG; Petinom, C, 1996) |
| "Ofloxacin (OFLX), having superior antileprosy activity among the various quinolones, was studied for its combined therapeutic efficacy with rifampin (RMP) against Mycobacterium leprae infection induced in nude mice." | 3.68 | Therapeutic efficacy of some new quinolones and a combination of ofloxacin with rifampin against Mycobacterium leprae infection induced in athymic nude mice. ( Saito, H; Tomioka, H, 1993) |
| "The bactericidal activities against Mycobacterium leprae of single or multiple doses of various combinations of new antileprosy drugs [minocycline (MINO), clarithromycin (CLARI), ofloxacin (OFLO), and sparfloxacin (SPFX)] and/or rifampin (RMP) were titrated in immunocompetent mice by the proportional bactericidal method." | 3.68 | Bactericidal activities of single or multiple doses of various combinations of new antileprosy drugs and/or rifampin against M. leprae in mice. ( Grosset, JH; Ji, B; Perani, EG; Petinon, C, 1992) |
| "In a clinical trial including 17 multibacillary leprosy patients the in vivo effectiveness of ofloxacin on Mycobacterium leprae was tested via mass spectrometric determination of intrabacterial ratios of the concentrations of the sodium and potassium ions of individual organisms and of the ATP content per 10(6) bacteria isolated from skin biopsies." | 3.68 | Intrabacterial sodium-to-potassium ratios and ATP contents of Mycobacterium leprae from ofloxacin-treated patients. ( Dhople, AM; Dietz, M; Haas, M; Lindner, B; Seydel, U; Tebebe, YB, 1991) |
| " In many cases dose and intervals were based on WHO protocol, however smaller dosage was used in some cases." | 2.40 | [Chemotherapy of Hansen's disease in Japan--present status]. ( Goto, M; Kitajima, S; Miyagi, S; Takizawa, H, 1998) |
| "Histoid leprosy is a rare but well-defined entity with specific clinical, histopathologic, and bacteriologic features." | 1.38 | Histoid leprosy: case report. ( Attia, AM; Bakry, OA, 2012) |
| "Leprosy affects skin and peripheral nerves, and acute inflammatory type 1 reactions (reversal reaction) can cause neurologic impairment and disabilities." | 1.34 | Mycobacterium leprae DNA associated with type 1 reactions in single lesion paucibacillary leprosy treated with single dose rifampin, ofloxacin, and minocycline. ( Costa, MB; Gillis, TP; Gomes, MK; Krahenbuhl, JL; Martelli, CM; Narahashi, K; Pereira, GA; Rebello, PF; Sousa, AL; Stefani, MM, 2007) |
| "The antimicrobial effects of sitafloxacin (DU-6859a) against Mycobacterium leprae, either singly or in combination with either rifampicin, rifabutin or KRM-1648, were studied using a mouse footpad assay technique and the results were compared with those obtained with ofloxacin." | 1.32 | In vivo susceptibility of Mycobacterium leprae to sitafloxacin (DU-6859a), either singly or in combination with rifampicin analogues. ( Dhople, AM; Namba, K, 2003) |
| "In the present study, we evaluated the in vivo anti-Mycobacterium leprae activities of KRM-1648 (KRM) given at long intervals in combination with ofloxacin (OFLX), clofazimine (CFZ), and dapsone (DDS)." | 1.30 | Studies on therapeutic activity of benzoxazinorifamycin KRM-1648 in combination with other antimicrobial agents and biological response modifiers interferon-gamma and granulocyte-macrophage colony-stimulating factor against M. leprae infection in athymic ( Maw, WW; Saito, H; Sato, K; Tomioka, H, 1997) |
| "Sparfloxacin was significantly more bactericidal than ofloxacin at all doses, and the results with 25 mg/kg sparfloxacin were nearly identical to those obtained with 100 mg/kg ofloxacin." | 1.29 | Sparfloxacin is more bactericidal than ofloxacin against Mycobacterium leprae in mice. ( Chan, GP; Franzblau, SG; Parrilla, ML, 1993) |
| "The antimicrobial effects of ofloxacin against Mycobacterium leprae, either alone or in combination with rifampicin and rifabutin, were studied using mouse foot pad assay technique." | 1.29 | In vivo susceptibility of Mycobacterium leprae to ofloxacin either singly or in combination with rifampicin and rifabutin. Anti-leprosy activity of ofloxacin and ansamycins in mice. ( Dhople, AM; Ibanez, MA, 1994) |
| " The treatment of mice with the smaller dosage ofloxacin, with pefloxacin, prothionamide, or dapsone uniformly resulted in a delay of multiplication of 4 months, compared to the multiplication of M." | 1.27 | Activity of ofloxacin against Mycobacterium leprae in the mouse. ( Beoletto, C; Grosset, JH; Guelpa-Lauras, CC; Perani, EG, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (5.19) | 18.7374 |
| 1990's | 33 (42.86) | 18.2507 |
| 2000's | 22 (28.57) | 29.6817 |
| 2010's | 12 (15.58) | 24.3611 |
| 2020's | 6 (7.79) | 2.80 |
| Authors | Studies |
|---|---|
| Bera, S | 1 |
| Mondal, D | 1 |
| Ahuja, M | 3 |
| Singh, I | 4 |
| Lavania, M | 3 |
| Pathak, VK | 2 |
| Darlong, J | 2 |
| Turankar, RP | 2 |
| Hembrom, S | 1 |
| Singh, SV | 1 |
| Sengupta, U | 2 |
| Li, X | 1 |
| Li, G | 1 |
| Yang, J | 1 |
| Jin, G | 1 |
| Shao, Y | 1 |
| Li, Y | 1 |
| Wei, P | 1 |
| Zhang, L | 1 |
| Muddebihal, A | 1 |
| Sardana, K | 1 |
| Khurana, A | 1 |
| Sachdeva, S | 1 |
| Sharma, R | 3 |
| Chhabra, S | 1 |
| Narang, T | 1 |
| Sahu, S | 1 |
| Sharma, K | 1 |
| Shilpa, S | 1 |
| Sharma, A | 1 |
| Jain, S | 1 |
| Yadav, R | 1 |
| Kaur, M | 1 |
| Nadeem, M | 1 |
| Pandey, P | 1 |
| Minz, RW | 1 |
| Dogra, S | 1 |
| Park, JH | 1 |
| Yamaguchi, T | 1 |
| Ouchi, Y | 1 |
| Koide, K | 1 |
| Mori, S | 1 |
| Kim, H | 1 |
| Mukai, T | 1 |
| Nakajima, C | 2 |
| Suzuki, Y | 3 |
| Kumar, A | 1 |
| Nathan, R | 1 |
| Araujo, S | 1 |
| Goulart, LR | 1 |
| Truman, RW | 1 |
| Goulart, IMB | 1 |
| Vissa, V | 2 |
| Li, W | 2 |
| Matsuoka, M | 8 |
| Suffys, P | 2 |
| Fontes, AB | 1 |
| Rosa, PS | 2 |
| Scollard, DM | 1 |
| Williams, DL | 1 |
| Bonnar, PE | 1 |
| Cunningham, NP | 1 |
| Boggild, AK | 1 |
| Walsh, NM | 1 |
| Davis, IRC | 1 |
| Cambau, E | 2 |
| Saunderson, P | 1 |
| Cole, ST | 1 |
| Kai, M | 2 |
| Williams, D | 1 |
| Gupta, UD | 2 |
| Cardona-Castro, N | 2 |
| Miyamoto, Y | 1 |
| Hagge, D | 1 |
| Srikantam, A | 1 |
| Hongseng, W | 1 |
| Indropo, A | 1 |
| Johnson, RC | 1 |
| Cauchoix, B | 1 |
| Pannikar, VK | 1 |
| Cooreman, EAWD | 1 |
| Pemmaraju, VRR | 1 |
| Gillini, L | 1 |
| Liu, D | 1 |
| Zhang, Q | 1 |
| Sun, Y | 1 |
| Wang, C | 1 |
| Zhang, Y | 1 |
| Fu, X | 1 |
| Chen, M | 1 |
| Zhou, G | 1 |
| Yu, X | 1 |
| Wang, J | 1 |
| Liu, H | 1 |
| Zhang, F | 1 |
| Beltrán-Alzate, C | 1 |
| López Díaz, F | 1 |
| Romero-Montoya, M | 1 |
| Sakamuri, R | 1 |
| Kimura, M | 1 |
| Brennan, P | 1 |
| Garcia, IE | 1 |
| Fafutis-Morris, M | 1 |
| Vargas-González, A | 1 |
| Carreño-Martinez, C | 1 |
| Fukushima, Y | 1 |
| Sekar, B | 1 |
| Arunagiri, K | 1 |
| Kumar, BN | 1 |
| Narayanan, S | 1 |
| Menaka, K | 1 |
| Oommen, PK | 1 |
| Setia, MS | 1 |
| Shinde, SS | 1 |
| Jerajani, HR | 1 |
| Boivin, JF | 1 |
| Shetty, VP | 2 |
| Wakade, AV | 2 |
| Ghate, SD | 1 |
| Pai, VV | 8 |
| Bakry, OA | 1 |
| Attia, AM | 1 |
| Lockwood, DN | 3 |
| Cunha, Mda G | 1 |
| Revankar, CR | 5 |
| Bulchand, HO | 4 |
| Ganapati, R | 7 |
| Pattyn, S | 2 |
| Grillone, S | 2 |
| Dhople, AM | 3 |
| Namba, K | 1 |
| Stefani, MM | 2 |
| Martelli, CM | 2 |
| Gillis, TP | 2 |
| Krahenbuhl, JL | 2 |
| Villahermosa, LG | 1 |
| Fajardo, TT | 1 |
| Abalos, RM | 1 |
| Cellona, RV | 1 |
| Balagon, MV | 1 |
| Dela Cruz, EC | 1 |
| Tan, EV | 1 |
| Walsh, GP | 1 |
| Walsh, DS | 1 |
| Gidoh, M | 2 |
| Namisato, M | 2 |
| Kumano, K | 1 |
| Goto, M | 2 |
| Nogami, R | 1 |
| Ozaki, M | 2 |
| Maeda, S | 2 |
| Biswas, SK | 1 |
| Yamazaki, T | 1 |
| Ishikawa, M | 1 |
| Ludwig, RJ | 1 |
| Henke, U | 1 |
| Wolter, M | 1 |
| Walker, SL | 1 |
| Brandt, C | 1 |
| Wichelhaus, TA | 1 |
| Kramme, S | 1 |
| Kaufmann, R | 1 |
| Sousa, AL | 1 |
| Pereira, GA | 1 |
| Costa, MB | 1 |
| Rebello, PF | 1 |
| Gomes, MK | 1 |
| Narahashi, K | 1 |
| Oo, KN | 1 |
| Yin, NN | 1 |
| Han, TT | 1 |
| Wai, KT | 1 |
| Myint, K | 1 |
| Gyi, MM | 1 |
| Ibanez, MA | 1 |
| McDermott-Lancaster, RD | 3 |
| Banerjee, DK | 3 |
| Franzblau, SG | 1 |
| Parrilla, ML | 1 |
| Chan, GP | 1 |
| Tomioka, H | 4 |
| Saito, H | 4 |
| Sampoonachot, P | 2 |
| Bundit, C | 2 |
| Kuhacharoen, N | 2 |
| Peerapakorn, S | 2 |
| Kampirapap, K | 2 |
| Poomlek, A | 2 |
| Bampenyu, S | 2 |
| Tiasiri, S | 2 |
| Rungruang, S | 2 |
| Surasondhi, S | 2 |
| Supanwanit, S | 2 |
| Wiriyawipart, S | 2 |
| Ji, B | 6 |
| Perani, EG | 3 |
| Petinom, C | 1 |
| Grosset, JH | 6 |
| Mochizuki, Y | 1 |
| Oishi, M | 1 |
| Nishiyama, C | 1 |
| Iida, T | 1 |
| McKenzie, S | 1 |
| Mane, I | 1 |
| Cartel, JL | 1 |
| Maw, WW | 1 |
| Sato, K | 2 |
| Sow, S | 1 |
| Perani, E | 2 |
| Lienhardt, C | 1 |
| Diderot, V | 1 |
| Grosset, J | 2 |
| Kingsley, S | 2 |
| Ramu, G | 1 |
| Miyagi, S | 1 |
| Takizawa, H | 1 |
| Kitajima, S | 1 |
| Franzblau, S | 1 |
| Samy, MS | 1 |
| Diletto, C | 2 |
| Daulako, EC | 1 |
| Tin, K | 1 |
| Singh, HB | 1 |
| Katoch, K | 1 |
| Natrajan, M | 1 |
| Sharma, RK | 1 |
| Sharma, VD | 1 |
| Singh, D | 1 |
| Chauhan, DS | 1 |
| Srivastava, K | 1 |
| Katoch, VM | 1 |
| Blanc, L | 1 |
| Levy, L | 1 |
| Gupte, MD | 1 |
| Shinde, A | 1 |
| Khopkar, U | 1 |
| Kashiwabara, Y | 2 |
| Antia, NH | 1 |
| Revenker, CR | 1 |
| Nakata, N | 1 |
| Maeda, Y | 1 |
| Hashimoto, K | 1 |
| Kimura, H | 1 |
| Kobayashi, K | 1 |
| Bonnafous, P | 1 |
| Sougakoff, W | 1 |
| Jarlier, V | 1 |
| Petinon, C | 1 |
| Gunby, P | 1 |
| Dietz, M | 1 |
| Haas, M | 1 |
| Lindner, B | 1 |
| Tebebe, YB | 1 |
| Seydel, U | 1 |
| Guelpa-Lauras, CC | 1 |
| Beoletto, C | 1 |
| Pattyn, SR | 1 |
| Nagashima, K | 1 |
7 reviews available for ofloxacin and Leprosy
| Article | Year |
|---|---|
Insights of synthetic analogues of anti-leprosy agents.
Topics: Humans; Leprostatic Agents; Leprosy; Structure-Activity Relationship | 2019 |
Drug Resistance (Dapsone, Rifampicin, Ofloxacin) and Resistance-Related Gene Mutation Features in Leprosy Patients: A Systematic Review and Meta-Analysis.
Topics: Amino Acids; Dapsone; Drug Resistance, Bacterial; Humans; Leprostatic Agents; Leprosy; Microbial Sen | 2022 |
Is there a role for rifampicin, ofloxacin and minocycline (ROM) therapy in the treatment of leprosy? Systematic review and meta-analysis.
Topics: Anti-Bacterial Agents; Drug Combinations; Drug Therapy, Combination; Humans; Leprostatic Agents; Lep | 2011 |
[DNA microarray based rapid drug susceptibility test for Mycobacterium leprae].
Topics: Animals; Dapsone; Drug Resistance, Microbial; Humans; Leprostatic Agents; Leprosy; Mice; Microbial S | 2006 |
[Chemotherapy of Hansen's disease in Japan--present status].
Topics: Anti-Infective Agents; Clofazimine; Drug Administration Schedule; Drug Therapy, Combination; Humans; | 1998 |
Ofloxacin for the treatment of leprosy.
Topics: Animals; Humans; Leprosy; Mycobacterium leprae; Ofloxacin | 1991 |
Pharmacokinetics in drug screening.
Topics: Animals; Biological Availability; Body Weight; Dapsone; Drug Evaluation, Preclinical; Humans; Lepros | 1987 |
9 trials available for ofloxacin and Leprosy
| Article | Year |
|---|---|
Parallel assessment of 24 monthly doses of rifampin, ofloxacin, and minocycline versus two years of World Health Organization multi-drug therapy for multi-bacillary leprosy.
Topics: Adolescent; Adult; Clofazimine; Dapsone; Drug Therapy, Combination; Female; Humans; Leprostatic Agen | 2004 |
Serological response to chemoprophylaxis in extended contacts in leprosy--a randomized controlled trial.
Topics: Adolescent; Adult; Antibiotic Prophylaxis; Antibodies, Bacterial; Child; Cohort Studies; Drug Therap | 2008 |
Combined chemotherapy trials with regimens containing ofloxacin and rifampicin for multibacillary leprosy patients.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Child; Drug Therapy, Combination; Female; Follow-Up | 1996 |
Field trial on efficacy of supervised monthly dose of 600 mg rifampin, 400 mg ofloxacin and 100 mg minocycline for the treatment of leprosy; first results.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Child; Drug Therapy, Combination; F | 1997 |
Rifampicin/minocycline and ofloxacin (ROM) for single lesions--what is the evidence?
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Drug Combinations; Drug Therapy, Combination; Humans; | 1997 |
Bactericidal activity of a single-dose combination of ofloxacin plus minocycline, with or without rifampin, against Mycobacterium leprae in mice and in lepromatous patients.
Topics: Adolescent; Adult; Animals; Drug Therapy, Combination; Female; Humans; Leprostatic Agents; Leprosy; | 1998 |
Single-dose rifampicin, oflaxicin and minocycline (ROM) therapy for single leprosy lesions.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Dose-Response Relationship, Drug; Drug Therapy, Combin | 1998 |
Ofloxacin containing combined drug regimens in the treatment of multibacillary leprosy.
Topics: Adolescent; Adult; Aged; Animals; Child; Dose-Response Relationship, Drug; Female; Humans; Leprostat | 1997 |
A 6 week quadruple drug regimen for the treatment of multibacillary leprosy.
Topics: Clofazimine; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hum | 2000 |
61 other studies available for ofloxacin and Leprosy
| Article | Year |
|---|---|
Ofloxacin resistance in multibacillary new leprosy cases from Purulia, West Bengal: a threat to effective secondary line treatment for rifampicin-resistant leprosy cases.
Topics: Animals; Dapsone; Drug Resistance, Bacterial; Leprostatic Agents; Leprosy; Mice; Mycobacterium lepra | 2022 |
A prospective case control study of resistance to rifampicin, dapsone and ofloxacin in Type 1 and Type 2 leprosy reactions and the therapeutic impact of modified treatment regimen on reactions.
Topics: Case-Control Studies; Dapsone; Drug Therapy, Combination; Humans; Hypersensitivity; Leprostatic Agen | 2023 |
High frequency of ofloxacin resistance patterns of Mycobacterium leprae from India: An indication to revisit second line anti-leprosy treatment regimen.
Topics: Cross-Sectional Studies; Dapsone; Drug Resistance, Bacterial; Drug Therapy, Combination; Humans; Ind | 2023 |
WQ-3810 inhibits DNA gyrase activity in ofloxacin-resistant Mycobacterium leprae.
Topics: Anti-Bacterial Agents; Azetidines; DNA Gyrase; Drug Resistance, Bacterial; Fluoroquinolones; Humans; | 2020 |
Analysis of bacteriological Index between fixed multidrug therapy and new WHO recommended alternative regimen with ofloxacin, minocycline and clofazimine of rifampicin resistant cases from the hospitals of The Leprosy Mission, India.
Topics: Clofazimine; Drug Therapy, Combination; Hospitals; Humans; India; Leprostatic Agents; Leprosy; Minoc | 2020 |
qPCR-High resolution melt analysis for drug susceptibility testing of Mycobacterium leprae directly from clinical specimens of leprosy patients.
Topics: Bacterial Proteins; Dapsone; DNA, Bacterial; Drug Resistance, Bacterial; Humans; Leprostatic Agents; | 2017 |
Leprosy in Nonimmigrant Canadian Man without Travel outside North America, 2014.
Topics: Aged; Anti-Bacterial Agents; Canada; Dapsone; Drug Therapy, Combination; Florida; Humans; Leprostati | 2018 |
Antimicrobial resistance in leprosy: results of the first prospective open survey conducted by a WHO surveillance network for the period 2009-15.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Biopsy, Needle; Brazil; Colombia; Dapsone; DNA Gyrase; Dr | 2018 |
Drug resistance in Mycobacterium leprae from patients with leprosy in China.
Topics: Adult; Bacterial Proteins; China; Dapsone; DNA, Bacterial; Drug Resistance, Bacterial; Female; Human | 2015 |
Leprosy Drug Resistance Surveillance in Colombia: The Experience of a Sentinel Country.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Proteins; Child; Colombia; Dapsone; DNA, Bacte | 2016 |
Possible mode of emergence for drug-resistant leprosy is revealed by an analysis of samples from Mexico.
Topics: Bacterial Proteins; Dapsone; DNA Gyrase; DNA, Bacterial; Drug Resistance, Bacterial; Drug Therapy, C | 2010 |
Detection of mutations in folp1, rpoB and gyrA genes of M. leprae by PCR- direct sequencing--a rapid tool for screening drug resistance in leprosy.
Topics: Animals; Bacterial Proteins; Biopsy; Clofazimine; Cross-Sectional Studies; Dapsone; Dihydropteroate | 2011 |
Clinical, bacteriological and histopathological study of 62 referral relapse cases between Jan 2004 and Dec 2009 at the Foundation for Medical Research, Mumbai.
Topics: Academies and Institutes; Adult; Aged; Biomedical Research; Drug Therapy, Combination; Female; Follo | 2011 |
Histoid leprosy: case report.
Topics: Aged; Atrophy; Dermis; Epidermis; Humans; Leprostatic Agents; Leprosy; Male; Minocycline; Ofloxacin; | 2012 |
Developing new MDT regimens for MB patients; time to test ROM 12 month regimens globally.
Topics: Clofazimine; Dapsone; Drug Administration Schedule; Drug Therapy, Combination; Humans; Leprostatic A | 2012 |
Single-dose ROM treatment for multilesion paucibacillary leprosy--further observations.
Topics: Clinical Trials as Topic; Drug Therapy, Combination; Humans; Leprostatic Agents; Leprosy; Minocyclin | 2002 |
Relapse rates and a 10-year follow-up of a 6-week quadruple drug regimen for multibacillary leprosy.
Topics: Belgium; Clofazimine; Drug Administration Schedule; Drug Therapy, Combination; Follow-Up Studies; Hu | 2002 |
In vivo susceptibility of Mycobacterium leprae to sitafloxacin (DU-6859a), either singly or in combination with rifampicin analogues.
Topics: Animals; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Fluoroquinolones; Leprostati | 2003 |
In situ type 1 cytokine gene expression and mechanisms associated with early leprosy progression.
Topics: Adolescent; Adult; Antibodies, Bacterial; Biopsy; Child; Cohort Studies; Cytokines; Female; Gene Exp | 2003 |
[Guideline for the treatment of leprosy by new quinolones].
Topics: Anti-Infective Agents; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Humans; Lepr | 2004 |
[Multi-drug resistant Mycobacterium leprae from patients with leprosy].
Topics: Animals; Base Sequence; Dapsone; DNA Gyrase; DNA-Directed RNA Polymerases; Drug Resistance, Multiple | 2004 |
Chemotherapy of leprosy.
Topics: Anti-Bacterial Agents; Clofazimine; Dapsone; Dose-Response Relationship, Drug; Drug Combinations; Dr | 2004 |
[Basic evaluation for new antimicrobial susceptibility testing of Mycobacterium leprae by bioluminescence assay (ATP method)].
Topics: Animals; Clarithromycin; Clofazimine; Drug Resistance, Bacterial; Leprostatic Agents; Leprosy; Lucif | 2006 |
[Long-term follow-up of ofloxacin-combined therapy for leprosy patients].
Topics: Aged; Anti-Bacterial Agents; Clofazimine; Cystamine; Drug Therapy, Combination; Follow-Up Studies; H | 2007 |
Persistence of peri-neural granulomas after successful treatment of leprosy.
Topics: Diagnosis, Differential; Drug Therapy, Combination; Granuloma; Humans; Leprostatic Agents; Leprosy; | 2007 |
Mycobacterium leprae DNA associated with type 1 reactions in single lesion paucibacillary leprosy treated with single dose rifampin, ofloxacin, and minocycline.
Topics: Adolescent; Adult; Aging; Cohort Studies; DNA, Bacterial; Erythema Nodosum; Female; Humans; Leprosy; | 2007 |
In vivo susceptibility of Mycobacterium leprae to ofloxacin either singly or in combination with rifampicin and rifabutin. Anti-leprosy activity of ofloxacin and ansamycins in mice.
Topics: Animals; Armadillos; Drug Synergism; Female; Foot; Leprostatic Agents; Leprosy; Liver; Mice; Mice, I | 1994 |
Activity of sparfloxacin against Mycobacterium leprae measured by the proportional bactericidal test.
Topics: Animals; Anti-Infective Agents; Antitubercular Agents; Colony Count, Microbial; Disease Models, Anim | 1993 |
Sparfloxacin is more bactericidal than ofloxacin against Mycobacterium leprae in mice.
Topics: Animals; Female; Fluoroquinolones; Leprosy; Mice; Mice, Inbred BALB C; Mycobacterium leprae; Ofloxac | 1993 |
Therapeutic efficacy of some new quinolones and a combination of ofloxacin with rifampin against Mycobacterium leprae infection induced in athymic nude mice.
Topics: Animals; Disease Models, Animal; Drug Therapy, Combination; Female; Leprosy; Mice; Mice, Inbred BALB | 1993 |
Bactericidal activities of combinations of new drugs against Mycobacterium leprae in nude mice.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Clarithromycin; Colony Count, Microbial; Drug | 1996 |
Active leprosy treated effectively with ofloxacin.
Topics: Adult; Anti-Infective Agents; Biopsy; Humans; Leprosy; Male; Ofloxacin; Skin | 1996 |
Experimental evaluation of possible new short-term drug regimens for treatment of multibacillary leprosy.
Topics: Animals; Clarithromycin; Drug Therapy, Combination; Leprostatic Agents; Leprosy; Mice; Mice, Nude; M | 1997 |
Studies on therapeutic activity of benzoxazinorifamycin KRM-1648 in combination with other antimicrobial agents and biological response modifiers interferon-gamma and granulocyte-macrophage colony-stimulating factor against M. leprae infection in athymic
Topics: Adoptive Transfer; Animals; Clofazimine; Dapsone; Drug Therapy, Combination; Female; Granulocyte-Mac | 1997 |
[High prevalence of leprosy in the Federated States of Micronesia and special project for the elimination].
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Child; Drug Therapy, Combination; Humans; Lepro | 1997 |
[New WHO recommendations for the treatment of leprosy].
Topics: Clofazimine; Dapsone; Drug Therapy, Combination; Humans; Leprostatic Agents; Leprosy; Minocycline; M | 1997 |
Relapse of multibacillary leprosy after rifampin and ofloxacin treatment for 28 days; a case report.
Topics: Adult; Drug Therapy, Combination; Humans; Leprosy; Male; Ofloxacin; Recurrence; Rifampin | 1998 |
Relapse of multibacillary leprosy after treatment with daily rifampin plus ofloxacin for four weeks.
Topics: Anti-Infective Agents; Drug Therapy, Combination; Humans; Leprostatic Agents; Leprosy; Ofloxacin; Re | 1998 |
Report of workshop on chemotherapy.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Drug Therapy, Combination; Humans; Leprostatic Agents; | 1998 |
Single-dose treatment for paucibacillary leprosy; feasibility of long-term follow up.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Community Health Workers; Drug Therapy, Combination; H | 1999 |
Single-dose treatment for paucibacillary leprosy; clinical problems and management.
Topics: Adolescent; Anti-Bacterial Agents; Anti-Infective Agents; Child; Clofazimine; Drug Therapy, Combinat | 1999 |
Single-dose treatment for paucibacillary leprosy; field implications.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Cohort Studies; Confidence Intervals; Drug Therapy, Co | 1999 |
Elimination of leprosy in the federated states of micronesia by intensive case finding, treatment with WHO/MDT and administration of chemoprophylaxis.
Topics: Adolescent; Adult; Chemoprevention; Humans; Leprostatic Agents; Leprosy; Micronesia; Minocycline; Of | 1999 |
Population screening and mass chemoprophylaxis in Kiribati.
Topics: Adolescent; Chemoprevention; Child; Child, Preschool; Communicable Disease Control; Humans; Leprosta | 1999 |
Population screening and chemoprophylaxis for household contacts of leprosy patients in the Republic of the Marshall Islands.
Topics: Chemoprevention; Contact Tracing; Drug Therapy, Combination; Leprostatic Agents; Leprosy; Mass Scree | 1999 |
Effect of treatment on PCR positivity in multibacillary leprosy patients treated with conventional and newer drugs ofloxacin and minocycline.
Topics: Adenosine Triphosphate; Biopsy; Clofazimine; Dapsone; DNA, Bacterial; Drug Evaluation; Drug Therapy, | 1999 |
Leprosy chemoprophylaxis in Micronesia.
Topics: Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Incidence; Leprostatic Agents; Leprosy | 2000 |
Field trials of a single dose of the combination rifampicin-ofloxacin-minocycline (ROM) for the treatment of paucibacillary leprosy.
Topics: Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Therapy, Combination; India; Lepros | 2000 |
Single-dose treatment for single lesion leprosy; histopathological observations.
Topics: Anti-Infective Agents; Drug Therapy, Combination; Granuloma; Humans; Leprostatic Agents; Leprosy; Mi | 2000 |
A Mycobacterium leprae isolate resistant to dapsone, rifampin, ofloxacin and sparfloxacin.
Topics: Animals; Anti-Infective Agents; Antitubercular Agents; Clarithromycin; Clofazimine; Colony Count, Mi | 2000 |
Clinical, histopathological and bacteriological investigations in two cases of relapse following ROM treatment.
Topics: Adult; Animals; Drug Therapy, Combination; Female; Humans; Leprostatic Agents; Leprosy; Male; Mice; | 2001 |
Multidrug resistant Mycobacterium leprae from patients with leprosy.
Topics: Animals; Anti-Infective Agents; Antibiotics, Antitubercular; Base Sequence; DNA Primers; DNA, Bacter | 2001 |
Molecular detection of rifampin and ofloxacin resistance for patients who experience relapse of multibacillary leprosy.
Topics: Adult; Aged; Antibiotics, Antitubercular; Disease Models, Animal; DNA Gyrase; DNA-Directed RNA Polym | 2002 |
Bactericidal activities of single or multiple doses of various combinations of new antileprosy drugs and/or rifampin against M. leprae in mice.
Topics: Animals; Clarithromycin; Disease Models, Animal; Female; Fluoroquinolones; Foot; Hindlimb; Immunocom | 1992 |
An experimental study to evaluate the bactericidal activity of ofloxacin against an established Mycobacterium leprae infection.
Topics: Animals; Dapsone; Disease Models, Animal; Drug Therapy, Combination; Leprosy; Mice; Mice, Nude; Myco | 1992 |
Can leprosy be neutralized by year 2000?
Topics: Bacterial Vaccines; Global Health; Humans; Leprosy; Mycobacterium leprae; Ofloxacin; Prevalence; Rif | 1992 |
Comparative in vitro and in vivo activity of fleroxacin and ofloxacin against various mycobacteria.
Topics: Animals; Disease Models, Animal; Female; Fleroxacin; Leprosy; Mice; Mice, Inbred BALB C; Microbial S | 1991 |
Intrabacterial sodium-to-potassium ratios and ATP contents of Mycobacterium leprae from ofloxacin-treated patients.
Topics: Adenosine Triphosphate; Adolescent; Adult; Aged; Biopsy; Electrolytes; Female; Humans; Leprosy; Male | 1991 |
Activity of ofloxacin against Mycobacterium leprae in the mouse.
Topics: Animals; Anti-Bacterial Agents; Dapsone; Female; Leprosy; Mice; Mycobacterium leprae; Norfloxacin; O | 1988 |
Activity of ofloxacin and pefloxacin against Mycobacterium leprae in mice.
Topics: Animals; Drug Evaluation, Preclinical; Leprosy; Mice; Norfloxacin; Ofloxacin; Oxazines; Pefloxacin | 1987 |
In vitro and in vivo activities of ofloxacin against Mycobacterium leprae infection induced in mice.
Topics: Animals; Female; Leprostatic Agents; Leprosy; Mice; Mycobacterium leprae; Ofloxacin; Oxazines | 1986 |